论文部分内容阅读
目的观察三维适形调强放疗联合替吉奥同步化疗治疗老年食管癌的临床效果。方法选取医院收治的老年食管癌患者89例为研究对象,按治疗方法不同分为单纯放疗组43例和同步放化疗组46例。单纯放疗组接受单一三维适形调强放疗治疗,同步放化疗组接受三维适形调强放疗联合替吉奥同步化疗治疗。观察比较2组患者的近期临床疗效、1年和2年生存率以及不良反应发生情况。结果同步放化疗组部分缓解率、总有效率分别为54.35%、82.61%,均高于单纯放疗组的32.56%、58.14%(P<0.05);同步放化疗组1年生存率和2年生存率分别为82.61%、56.52%,均高于单纯放疗组的53.49%、32.56%(P<0.01或P<0.05);同步放化疗组白细胞下降(Ⅲ~Ⅳ级)发生率、恶心和呕吐(Ⅰ~Ⅱ级)发生率分别为15.22%、47.83%,单纯放疗组的发生率分别为0、4.65%,2组差异有统计学意义(P<0.05)。结论三维适形调强放疗联合吉替奥同步化疗治疗老年食管癌的临床疗效明确可靠,效果较好,不良反应可以耐受,值得临床推广应用。
Objective To observe the clinical effect of three-dimensional conformal intensity-modulated radiation therapy combined with tegaserod for simultaneous chemotherapy in the treatment of esophageal cancer in the elderly. Methods A total of 89 elderly esophageal cancer patients admitted to hospital were selected as study subjects. According to the different treatment methods, 43 cases were treated with radiotherapy alone and 46 cases with concurrent radiotherapy and chemotherapy. Radiotherapy alone received a single three-dimensional conformal intensity modulated radiotherapy and radiotherapy and concurrent radiotherapy and chemotherapy group received three-dimensional conformal IMRT combined with TIGO simultaneous chemotherapy. The clinical efficacy, 1-year and 2-year survival rates and the incidence of adverse reactions in the two groups were observed and compared. Results The partial response rate and total effective rate of concurrent chemoradiotherapy group were 54.35% and 82.61%, respectively, which were higher than that of radiotherapy alone group (32.56%, 58.14%, P <0.05). The 1-year survival rate and 2-year survival rate The rates of leukopenia (Ⅲ ~ Ⅳ), nausea and vomiting (33.6%) in radiotherapy group were significantly higher than those in radiotherapy alone group (53.49% vs 32.56%, P <0.01 or P < Ⅰ ~ Ⅱ grade) were 15.22%, 47.83%, respectively, the incidence of radiotherapy alone was 0, 4.65%, the difference between the two groups was statistically significant (P <0.05). Conclusion Three-dimensional conformal IMRT combined with getinio concurrent chemotherapy in the treatment of esophageal cancer in elderly patients with clear and reliable clinical efficacy, better effect, adverse reactions can tolerate, worthy of clinical application.